Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

Karyopharm (Nasdaq: KPTI) announced that its senior management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 a.m. ET in New York.

A live webcast will be available under the company’s Investor "Events & Presentations" page and the presentation will be available for replay following the event.

NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 37^th Annual Healthcare Conference in a fireside chat on Thursday, December 4, 2025 at 10:30 a.m. ET in New York, NY.

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-piper-sandler-37th-annual-healthcare-conference-302624649.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm (KPTI) present at the Piper Sandler 37th Annual Healthcare Conference?

Karyopharm will present in a fireside chat on Thursday, December 4, 2025 at 10:30 a.m. ET.

How can investors watch the Karyopharm (KPTI) fireside chat on December 4, 2025?

Investors can watch a live webcast via the company’s Investor "Events & Presentations" page and view the replay afterward.

Where will the Piper Sandler conference fireside chat with Karyopharm (KPTI) be held?

The fireside chat will be held in New York, NY as part of the Piper Sandler 37th Annual Healthcare Conference.

Will Karyopharm (KPTI) make the presentation available after the Piper Sandler event?

Yes. The webcast will be available for replay on the company’s Investor "Events & Presentations" page following the event.

Which Karyopharm (KPTI) executives will participate in the December 4, 2025 fireside chat?

The announcement states the company’s senior management team will participate; specific names were not listed in the notice.

Where is the webcast link for Karyopharm (KPTI) events and presentations?

The webcast and replay will be accessible at https://investors.karyopharm.com/events-presentations.